184 related articles for article (PubMed ID: 28632940)
1. Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a).
Scipione CA; McAiney JT; Simard DJ; Bazzi ZA; Gemin M; Romagnuolo R; Macrae FL; Ariëns RA; Hegele RA; Auld J; Gauld JW; Boffa MB; Koschinsky ML
J Thromb Haemost; 2017 Sep; 15(9):1834-1844. PubMed ID: 28632940
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties.
Rowland CM; Pullinger CR; Luke MM; Shiffman D; Green L; Movsesyan I; Devlin JJ; Malloy MJ; Kane JP; Undas A
Thromb Res; 2014 May; 133(5):863-7. PubMed ID: 24502962
[TBL] [Abstract][Full Text] [Related]
3. Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis.
Boffa MB
Atherosclerosis; 2022 May; 349():72-81. PubMed ID: 35606079
[TBL] [Abstract][Full Text] [Related]
4. BβArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes.
Greenhalgh KA; Strachan MW; Alzahrani S; Baxter PD; Standeven KF; Storey RF; Ariens RA; Grant PJ; Price JF; Ajjan RA
Thromb Haemost; 2017 Jan; 117(2):295-302. PubMed ID: 27929198
[TBL] [Abstract][Full Text] [Related]
5. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles.
Arai K; Luke MM; Koschinsky ML; Miller ER; Pullinger CR; Witztum JL; Kane JP; Tsimikas S
Atherosclerosis; 2010 Apr; 209(2):498-503. PubMed ID: 19880117
[TBL] [Abstract][Full Text] [Related]
6. Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.
Boffa MB; Marar TT; Yeang C; Viney NJ; Xia S; Witztum JL; Koschinsky ML; Tsimikas S
J Lipid Res; 2019 Dec; 60(12):2082-2089. PubMed ID: 31551368
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts.
Laschkolnig A; Kollerits B; Lamina C; Meisinger C; Rantner B; Stadler M; Peters A; Koenig W; Stöckl A; Dähnhardt D; Böger CA; Krämer BK; Fraedrich G; Strauch K; Kronenberg F
Cardiovasc Res; 2014 Jul; 103(1):28-36. PubMed ID: 24760552
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of fibrinolysis by lipoprotein(a).
Anglés-Cano E; de la Peña Díaz A; Loyau S
Ann N Y Acad Sci; 2001; 936():261-75. PubMed ID: 11460483
[TBL] [Abstract][Full Text] [Related]
9. In vitro inhibition of fibrinolysis by apolipoprotein(a) and lipoprotein(a) is size- and concentration-dependent.
Knapp JP; Herrmann W
Clin Chem Lab Med; 2004; 42(9):1013-9. PubMed ID: 15497466
[TBL] [Abstract][Full Text] [Related]
10. Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform.
Undas A; Cieśla-Dul M; Drążkiewicz T; Sadowski J
Thromb Res; 2012 Sep; 130(3):e184-7. PubMed ID: 22762941
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Leebmann J; Lehmacher W; Kamstrup PR; Nordestgaard BG; Maerz W; Noureen A; Schmidt K; Kronenberg F; Heibges A; Klingel R;
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2019-27. PubMed ID: 27417585
[TBL] [Abstract][Full Text] [Related]
12. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator.
Anglés-Cano E; Hervio L; Rouy D; Fournier C; Chapman JM; Laplaud M; Koschinsky ML
Chem Phys Lipids; 1994 Jan; 67-68():369-80. PubMed ID: 8187237
[TBL] [Abstract][Full Text] [Related]
13. Mechanism for the homocysteine-enhanced antifibrinolytic potential of lipoprotein(a) in human plasma.
Nardulli M; Durlach V; Pepe G; Anglés-Cano E
Thromb Haemost; 2005 Jul; 94(1):75-81. PubMed ID: 16113787
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning of the cDNA encoding the carboxy-terminal domain of chimpanzee apolipoprotein(a): an Asp57 --> Asn mutation in kringle IV-10 is associated with poor fibrin binding.
Chenivesse X; Huby T; Wickins J; Chapman J; Thillet J
Biochemistry; 1998 May; 37(20):7213-23. PubMed ID: 9585533
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces.
Hancock MA; Boffa MB; Marcovina SM; Nesheim ME; Koschinsky ML
J Biol Chem; 2003 Jun; 278(26):23260-9. PubMed ID: 12697748
[TBL] [Abstract][Full Text] [Related]
16. Mapping of a minimal apolipoprotein(a) interaction motif conserved in fibrin(ogen) beta - and gamma -chains.
Klose R; Fresser F; Kochl S; Parson W; Kapetanopoulos A; Fruchart-Najib J; Baier G; Utermann G
J Biol Chem; 2000 Dec; 275(49):38206-12. PubMed ID: 10980194
[TBL] [Abstract][Full Text] [Related]
17. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?
Hervio L; Chapman MJ; Thillet J; Loyau S; Anglés-Cano E
Blood; 1993 Jul; 82(2):392-7. PubMed ID: 8329699
[TBL] [Abstract][Full Text] [Related]
18. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers.
Alzahrani SH; Hess K; Price JF; Strachan M; Baxter PD; Cubbon R; Phoenix F; Gamlen T; Ariëns RA; Grant PJ; Ajjan RA
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2282-7. PubMed ID: 22996148
[TBL] [Abstract][Full Text] [Related]
19. Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.
Janion-Sadowska A; Natorska J; Siudut J; Ząbczyk M; Stanisz A; Undas A
Thromb Haemost; 2017 Aug; 117(9):1739-1749. PubMed ID: 28771277
[TBL] [Abstract][Full Text] [Related]
20. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin.
Hervio L; Girard-Globa A; Durlach V; Anglés-Cano E
Eur J Clin Invest; 1996 May; 26(5):411-7. PubMed ID: 8796369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
